(Reuters) – French drugmaker Valneva has proposed a remediation plan after receiving the European Commission’s (EC) notice of intent to terminate the advance purchase agreement for its inactivated COVID-19 vaccine candidate.
“Some member states have confirmed their interest in having an inactivated, adjuvanted whole-virus vaccine solution in their portfolio,” the group said in a statement.
“However, the preliminary, unofficial volume indications received from the EC would not be sufficient to ensure the sustainability of Valneva’s COVID-19 vaccine program.”
(Reporting by Juliette Portala, editing by Angus MacSwan)
